NYSE:HIMSHealthcare
Assessing Hims & Hers Health (HIMS) Valuation After Regulatory And Legal Pressure On GLP 1 Offerings
The sharp move in Hims & Hers Health (HIMS) has centered on mounting legal and regulatory pressure, including Novo Nordisk’s patent lawsuit over compounded semaglutide products, FDA scrutiny of compounding practices, and a Department of Justice referral.
See our latest analysis for Hims & Hers Health.
At a share price of $16.30, Hims & Hers Health has experienced a sharp reset, with a 7 day share price return of 29.19% and a 30 day share price return of 47.96%. The 1 year total shareholder...